产品活性:Chrexanthomycin A 是一种具有显著生物活性的海洋天然产物,具有口服活性。Chrexanthomycin A 对 DNA (G4C2)4 G4 和 RNA (G4C2)2 G4 具有结合亲和力 Kd 值分别为 2.2 mM 和 3.0 mM。Chrexanthomycin A 可用于肌萎缩侧索硬化症(ALS)等神经退行性疾病的研究。
In Vitro: Chrexanthomycin A (Compounds cA) (0.1-10 mM) binds DNA (G4C2)4 G4 and RNA (G4C2)2 G4 with Kd values of 2.2 mM and 3.0 mM, respectively. Chrexanthomycin A shows the high permeability and low cytotoxicity to live cells. . Chrexanthomycin A (1.61 μM) rescues G4C2 EHR-related pathologies in cells. Chrexanthomycin A selectively binds to DNA and RNA G4C2 G4s. Chrexanthomycin A (0-100 μM) dramatically reduceS G4C2 EHR-caused cell death, diminish G4C2 RNA foci in (G4C2)29-expressing Neuro2a cells, and significantly eliminate ROS in HT22 cells.
In Vivo: Chrexanthomycin A (Compounds cA) (fed; 100 μM) significantly rescues eye degeneration and improve locomotor deficits in (G4C2)29-expressing.